NEW YORK, September 13, 2017 /PRNewswire/ --
If you want a Stock Review on CRIS, EGLT, or ESPR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, September 12, 2017, the NASDAQ Composite ended the trading session at 6,454.28, up 0.34%; the Dow Jones Industrial Average edged 0.28% higher to finish at 22,118.86; and the S&P 500 closed at 2,496.48, slightly advancing 0.34%. Gains were broad based as seven out of nine sectors ended the day in positive. This Wednesday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Curis Inc. (NASDAQ: CRIS), Egalet Corp. (NASDAQ: EGLT), and Esperion Therapeutics Inc. (NASDAQ: ESPR). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at: http://dailystocktracker.com/register/
On Tuesday, shares in Lexington, Massachusetts headquartered Curis Inc. recorded a trading volume of 379,014 shares. The stock ended the session 1.00% higher at $2.02. The Company's shares have advanced 17.44% in the last month, 16.76% in the previous three months. The stock is trading above its 50-day moving averages by 6.68%. Moreover, shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers in the US, have an RSI of 55.24. The complimentary research report on CRIS can be downloaded at: http://dailystocktracker.com/registration/?symbol=CRIS
Wayne, Pennsylvania headquartered Egalet Corp.'s shares closed the day 5.11% higher at $1.44. The stock recorded a trading volume of 335,292 shares. The Company's shares have gained 41.18% in the last month. The stock is trading above its 50-day moving average by 7.33%. Additionally, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 68.66. Register for free on DailyStockTracker.com and access the latest report on EGLT at: http://dailystocktracker.com/registration/?symbol=EGLT
Shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. finished 2.35% higher at $51.43. The stock recorded a trading volume of 646,237 shares. The Company's shares have advanced 46.07% in the previous three months, 364.17% over the last twelve months, and 310.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.03% and 61.09%, respectively. Furthermore, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 58.31.
On August 29th, 2017, research firm Northland Capital initiated an 'Outperform' rating on the Company's stock with a target price of $72 per share. Get free access to your research report on ESPR at: http://dailystocktracker.com/registration/?symbol=ESPR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.